Related Experiment Video
Updated: May 21, 2025
00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.2K
Tubeimoside I Inhibits the Proliferation of Liver Cancer Through Inactivating NF-κB Pathway by Regulating TNFAIP3
Yajun Zhang1, Mingqin Zhou2, Liwen Zhu3
1Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Drug Design, Development and Therapy
|March 18, 2025
Summary
Tubeimoside I (TBMS1) from Bolbostemma paniculatum inhibits liver cancer growth by downregulating the NF-κB pathway and TNFAIP3 expression. This study supports TBMS1 as a potential therapeutic agent for liver cancer treatment.
Area of Science:
- Natural Product Chemistry
- Oncology
- Molecular Biology
Background:
- Liver cancer remains a significant global health challenge with limited effective treatments.
- Tubeimoside I (TBMS1) is a compound derived from the Chinese herb Bolbostemma paniculatum, known for its potential medicinal properties.
Purpose of the Study:
- To evaluate the therapeutic potential of TBMS1 in liver cancer treatment.
- To elucidate the molecular mechanisms underlying TBMS1's anticancer effects.
Main Methods:
- In vitro assays (CCK-8, colony formation, EDU, flow cytometry) assessed TBMS1 effects on liver cancer cell lines.
- RNA sequencing and network pharmacology identified TBMS1 targets and pathways.
- In vivo xenograft models evaluated antitumor efficacy.
Main Results:
- TBMS1 significantly inhibited liver cancer cell viability and proliferation while promoting apoptosis.
- NF-κB signaling pathway and TNFAIP3 expression were identified as key downstream targets.
- TBMS1 treatment markedly reduced tumor volume and weight in vivo.
Conclusions:
- TBMS1 exhibits potent anticancer activity against liver cancer by suppressing the NF-κB pathway and modulating TNFAIP3.
- These findings provide a strong theoretical foundation for developing TBMS1 as a novel liver cancer therapy.
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
01:22PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:31The Intrinsic Apoptotic Pathway
5.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.8K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K